ArticleScientific reports2025
Serum melatonin as a potential biomarker for COVID-19 severity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- High-Dose Intravenous Vitamin C in Critical Illness: A Translational Exposure-Response Framework for Biomarker-Guided Precision Therapy.Medical sciences (Basel, Switzerland) · 2026Review
- A novel insight into the femtosecond induced nonlinear response of monoamine neurotransmitters through experimental and in silico approaches.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the ongoing global burden of COVID-19, identifying reliable biomarkers to predict disease severity remains a clinical priority. Melatonin, a hormone with immunomodulatory and antioxidant properties, has garnered attention for its potential role in regulating inflammation during viral infections. However, the relationship between serum melatonin levels and COVID-19 severity remains poorly understood. This study aimed to evaluate the correlation between serum melatonin concentration and COVID-19 severity to identify potential prognostic biomarkers. A cohort study was conducted, including patients diagnosed with COVID-19 between June 2020 and July 2022. Serum melatonin levels in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) were measured and analyzed in relation to disease severity and oxygen requirements. In addition, serum melatonin level between survivors and non-survivors were also compared in this study. Patients not requiring oxygen therapy exhibited significantly higher serum melatonin levels (45.09 pg/mL) compared to those requiring intensive oxygen therapy (32.17 pg/mL) (p < 0.0001). Median serum melatonin levels were 41.57 pg/mL in survivors and 24.79 pg/mL in non-survivors (p = 0.0005). In addition, non-survivors with symptoms such as respiratory distress and stress displayed lower serum melatonin compared to survivors (p = 0.0022). Serum melatonin concentration at admission was found to be significantly lower in patients with critical or fatal COVID-19, suggesting that serum melatonin levels may serve as a potential biomarker for disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.